{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:04:07Z","timestamp":1793412247737,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T00:00:00Z","timestamp":1569628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T00:00:00Z","timestamp":1569628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00432-019-03027-6","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T07:02:36Z","timestamp":1569654156000},"page":"3067-3073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas"],"prefix":"10.1007","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-7580","authenticated-orcid":false,"given":"Frank","family":"Kroschinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Riemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Ordemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,28]]},"reference":[{"key":"3027_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/07357900701788098","volume":"26","author":"H Abali","year":"2008","unstructured":"Abali H, \u00dcr\u00fcn Y, \u00d6ks\u00fczo\u01e7lu B et al (2008) Comparison of ICE (Ifosfamide\u2013Carboplatin\u2013Etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 26:401\u2013406. \nhttps:\/\/doi.org\/10.1080\/07357900701788098","journal-title":"Cancer Invest"},{"key":"3027_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00689273","volume":"27","author":"KS Albain","year":"1990","unstructured":"Albain KS, Swinnen LJ, Erickson LC et al (1990) Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model. Cancer Chemother Pharmacol 27:33\u201340. \nhttps:\/\/doi.org\/10.1007\/BF00689273","journal-title":"Cancer Chemother Pharmacol"},{"key":"3027_CR3","first-page":"25","volume":"41","author":"J Bergerat","year":"1981","unstructured":"Bergerat J, Drewinko B, Corry P et al (1981) Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-\u03b2-d-arabinofuranosylcytosine. Cancer Res 41:25\u201330","journal-title":"Cancer Res"},{"key":"3027_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/amiajnl-2014-002631","volume":"21","author":"K Chida","year":"2014","unstructured":"Chida K, Morohashi G, Fuji H et al (2014) Implementation and evaluation of an efficient secure computation system using \u201cR\u201d for healthcare statistics. J Am Med Informatics Assoc 21:326\u2013331. \nhttps:\/\/doi.org\/10.1136\/amiajnl-2014-002631","journal-title":"J Am Med Informatics Assoc"},{"key":"3027_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J et al (2002) CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"3027_CR6","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S et al (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32:3490\u20133496. \nhttps:\/\/doi.org\/10.1200\/JCO.2013.53.9593","journal-title":"J Clin Oncol"},{"key":"3027_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s002280100319","volume":"57","author":"B Erdlenbruch","year":"2001","unstructured":"Erdlenbruch B, Nier M, Kern W et al (2001) Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 57:393\u2013402. \nhttps:\/\/doi.org\/10.1007\/s002280100319","journal-title":"Eur J Clin Pharmacol"},{"key":"3027_CR8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3324\/haematol.2010.025627","volume":"95","author":"CH Geisler","year":"2010","unstructured":"Geisler CH (2010) Front-line treatment of mantle cell lymphoma. Haematologica 95:1241\u20131243. \nhttps:\/\/doi.org\/10.3324\/haematol.2010.025627","journal-title":"Haematologica"},{"key":"3027_CR9","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184\u20134190. \nhttps:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol"},{"key":"3027_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s002779900150","volume":"79","author":"M H\u00e4nel","year":"2000","unstructured":"H\u00e4nel M, Kr\u00f6ger N, Hoffknecht MM et al (2000) ASHAP is an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 79:304\u2013311","journal-title":"Ann Hematol"},{"key":"3027_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s004320000226","volume":"127","author":"M H\u00e4nel","year":"2001","unstructured":"H\u00e4nel M, Kr\u00f6ger N, Kroschinsky F et al (2001) Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. J Cancer Res Clin Oncol 127:387\u2013395. \nhttps:\/\/doi.org\/10.1007\/s004320000226","journal-title":"J Cancer Res Clin Oncol"},{"key":"3027_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010.Research","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap)\u2014a metadata driven methodology and workflow process for providing translational research informatict support. J Biomed Inform 42:377\u2013381. \nhttps:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.Research","journal-title":"J Biomed Inform"},{"key":"3027_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J et al (2016) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65\u00a0years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N. Lancet 388:565\u2013575. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(16)00739-X","journal-title":"Lancet"},{"key":"3027_CR14","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: re. Blood 106:3725\u20133732","journal-title":"Blood"},{"key":"3027_CR15","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/annonc\/mdi248","volume":"16","author":"A Josting","year":"2005","unstructured":"Josting A, Sieniawski M, Glossmann JP et al (2005) High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma: results of a multicenter phase II study. Ann Oncol 16:1359\u20131365. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdi248","journal-title":"Ann Oncol"},{"key":"3027_CR16","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, M\u00fcller H, Borchmann P et al (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol 28:5074\u20135080. \nhttps:\/\/doi.org\/10.1200\/JCO.2010.30.5771","journal-title":"J Clin Oncol"},{"issue":"282","key":"3027_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Ass 53(282):457\u2013481","journal-title":"J Am Stat Ass"},{"key":"3027_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","volume":"13","author":"BW Mills","year":"2019","unstructured":"Mills BW, Chopra R, Mcmillan A et al (2019) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol 13:588\u2013595","journal-title":"J Clin Oncol"},{"key":"3027_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s002800050618","volume":"40","author":"N Nagai","year":"1997","unstructured":"Nagai N, Ogata H (1997) Quantitative relationship between pharmacokinetics of unchange cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 40:11\u201318. \nhttps:\/\/doi.org\/10.1007\/s002800050618","journal-title":"Cancer Chemother Pharmacol"},{"key":"3027_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s002800050548","volume":"39","author":"N Nagai","year":"1996","unstructured":"Nagai N, Kinoshita M, Ogata H et al (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39:131\u2013137. \nhttps:\/\/doi.org\/10.1007\/s002800050548","journal-title":"Cancer Chemother Pharmacol"},{"key":"3027_CR21","first-page":"185","volume":"135","author":"R Peto","year":"1972","unstructured":"Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc 135:185\u2013207","journal-title":"J R Stat Soc"},{"key":"3027_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019S lymphoma. N Engl J Med 333:1540\u20131545","journal-title":"N Engl J Med"},{"key":"3027_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.1987.5.2.304","volume":"5","author":"PA Reece","year":"1987","unstructured":"Reece PA, Stafford I, Russell J et al (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5:304\u2013309. \nhttps:\/\/doi.org\/10.1200\/JCO.1987.5.2.304","journal-title":"J Clin Oncol"},{"key":"3027_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"JE Romaguera","year":"2010","unstructured":"Romaguera JE, Fayad LE, Feng L et al (2010) Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150:200\u2013208. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2010.08228.x","journal-title":"Br J Haematol"},{"key":"3027_CR25","first-page":"1383","volume":"49","author":"LJ Swinnen","year":"1989","unstructured":"Swinnen LJ, Barnes DM, Fisher SG et al (1989) 1-b-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum (II) and modification of palitnum-DNA interstrand crosslinking. Cancer Res 49:1383\u20131389","journal-title":"Cancer Res"},{"key":"3027_CR26","first-page":"1105","volume":"46","author":"H Vadi","year":"1986","unstructured":"Vadi H, Drewinko B (1986) Kinetics and mechanism of the 1-beta-d-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum (II) cytotoxicity. Cancer Res 46:1105\u20131109","journal-title":"Cancer Res"},{"key":"3027_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","volume":"71","author":"WS Velasquez","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P et al (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117\u2013122","journal-title":"Blood"},{"key":"3027_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"W Velasquez","year":"1994","unstructured":"Velasquez W, McLaughlin P, Tucker S et al (1994) ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169\u20131176","journal-title":"J Clin Oncol"},{"key":"3027_CR29","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/10428190801993470","volume":"49","author":"TE Witzig","year":"2008","unstructured":"Witzig TE, Geyer SM, Kurtin PJ et al (2008) Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the north central cancer treatment group. Leuk Lymphoma 49:1074\u20131080. \nhttps:\/\/doi.org\/10.1080\/10428190801993470","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-03027-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T23:34:01Z","timestamp":1601163241000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-03027-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,28]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3027"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-03027-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,28]]},"assertion":[{"value":"6 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}